Key result
Carriers of the KCNQ1 rs2237897 CT or TT genotypes achieved greater fasting plasma glucose reduction than CC carriers after 8 weeks of gliclazide monotherapy (3.9 vs 3.2 mmol/l, P=0.003).
Why the study?
Do KCNQ1 polymorphisms affect the efficacy of gliclazide in reducing fasting plasma glucose in newly diagnosed Chinese type 2 diabetic patients?
Cohort (n=443)
Do KCNQ1 polymorphisms affect the efficacy of gliclazide in reducing fasting plasma glucose in newly diagnosed Chinese type 2 diabetic patients?
Absolute Event Rate: 3.9% vs 3.2%
p-value: p=0.003
The KCNQ1 rs2237897 polymorphism is associated with the efficacy of gliclazide monotherapy in newly diagnosed Chinese type 2 diabetic patients, with CT and TT carriers showing greater FPG reduction.
Should not yet guide gliclazide dosing by KCNQ1 genotype; hypothesis-generating and requires prospective validation.
OBJECTIVES: To investigate the effects of KCNQ1 polymorphisms on the efficacy of gliclazide in type 2 diabetic patients. MATERIALS AND METHODS: A total of 443 newly diagnosed type 2 diabetic patients were included in this study. After enrollment, patients went on an 8-week gliclazide monotherapy. Fasting plasma glucose (FPG) was measured before and after the treatment. Life-style information was collected by weekly follow-up. Genotyping of the two single-nucleotide polymorphisms was performed using the single base primer extension method. T-test, one-way analysis of variance, and Pearson χ-test were used to evaluate the effects of rs2237892 and rs2237897 on the FPG reduction and treatment success rate. RESULTS: After 8 weeks of gliclazide therapy, the FPG decreased significantly from 10.9±2.8 to 7.4±2.2 mmol/l (P<0.001). Compared with the CC genotype, patients with CT or TT genotypes of rs2237897 achieved greater reduction in FPG (3.9±2.6 vs. 3.2±2.4 mmol/l, P=0.003; 33.9±19.0 vs. 27.7±17.4%, P<0.001) and a higher rate of treatment success (74.1 vs. 65.2%, P=0.042 for criterion 1; 61.1 vs. 44.5%, P<0.001 for criterion 2, respectively), whereas no significant difference was found in the FPG reduction and treatment success rate among different genotypes of rs2237892. CONCLUSION: Our results indicated that a common variant of KCNQ1, rs2237897, was associated with the efficacy of gliclazide after 8-week monotherapy in Chinese newly diagnosed type 2 diabetic patients. The FPG reduction and treatment success rate were significantly higher in carriers of CT and TT genotypes.
No takes yet. Share an insight, caveat, or question.
Duan et al. (2016) conducted a cohort in Type 2 diabetes (n=443). KCNQ1 rs2237897 CT or TT genotypes vs. CC genotype was evaluated on Fasting plasma glucose (FPG) reduction (mmol/l) (p=0.003). Carriers of the KCNQ1 rs2237897 CT or TT genotypes achieved greater fasting plasma glucose reduction than CC carriers after 8 weeks of gliclazide monotherapy (3.9 vs 3.2 mmol/l, P=0.003).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: